source
- Kelun-Biotech reports first-line success of Merck-partnered ADC sacituzumab tirumotecan in ChinaKelun-Biotech announced that its antibody‑drug conjugate sacituzumab tirumotecan, developed in partnership with Merck, achieved its primary efficacy endpoints when used as a first‑line therapy in a…
- Reporter attends AHA Leadership Summit in Denver to gauge hospital executives' prioritiesThe author attended the American Hospital Association’s Leadership Summit in downtown Denver earlier this week. While there, the author handed out ice cream recommendations to attendees. The prim…